MA35419B1 - Inhibiteurs de la tyrosine kinase de bruton - Google Patents

Inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
MA35419B1
MA35419B1 MA36783A MA36783A MA35419B1 MA 35419 B1 MA35419 B1 MA 35419B1 MA 36783 A MA36783 A MA 36783A MA 36783 A MA36783 A MA 36783A MA 35419 B1 MA35419 B1 MA 35419B1
Authority
MA
Morocco
Prior art keywords
compounds
inhibitors
tyrosine kinase
diseases associated
present
Prior art date
Application number
MA36783A
Other languages
English (en)
Inventor
Christine Brotherton-Pleiss
Saul Jaime-Figueroa
Francisco Javier Lopez-Tapia
Yan Lou
Timothy D Owens
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA35419B1 publication Critical patent/MA35419B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés selon la formule générique i : dans laquelle les variables sont telles que définies dans la description, et qui inhibent btk. Les composés décrits présentement sont utiles pour moduler l'activité de btk et traiter des maladies associées à une activité btk excessive. Les composés sont en outre utiles pour traiter des maladies inflammatoires et auto-immunes associées à une prolifération aberrante de lymphocytes b, telles que la polyarthrite rhumatoïde. La présente invention concerne en outre des compositions contenant des composés de formule i et au moins un véhicule, diluant ou excipient.
MA36783A 2011-08-17 2014-02-26 Inhibiteurs de la tyrosine kinase de bruton MA35419B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524374P 2011-08-17 2011-08-17
US201261649991P 2012-05-22 2012-05-22
PCT/EP2012/065844 WO2013024078A1 (fr) 2011-08-17 2012-08-14 Inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
MA35419B1 true MA35419B1 (fr) 2014-09-01

Family

ID=46690498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36783A MA35419B1 (fr) 2011-08-17 2014-02-26 Inhibiteurs de la tyrosine kinase de bruton

Country Status (23)

Country Link
US (1) US8889682B2 (fr)
EP (1) EP2744804B1 (fr)
JP (1) JP5823616B2 (fr)
KR (1) KR20140052032A (fr)
CN (1) CN103748088A (fr)
AR (1) AR087543A1 (fr)
AU (1) AU2012296888A1 (fr)
BR (1) BR112014003582A2 (fr)
CA (1) CA2841801A1 (fr)
CL (1) CL2014000350A1 (fr)
CO (1) CO6842020A2 (fr)
CR (1) CR20140027A (fr)
EA (1) EA024689B1 (fr)
EC (1) ECSP14013212A (fr)
HK (1) HK1197060A1 (fr)
IL (1) IL230561A0 (fr)
MA (1) MA35419B1 (fr)
MX (1) MX349372B (fr)
PE (1) PE20140865A1 (fr)
PH (1) PH12014500128A1 (fr)
TW (1) TW201311669A (fr)
WO (1) WO2013024078A1 (fr)
ZA (1) ZA201400739B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852964A1 (fr) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Composes piperazines bicycliques
TW201326171A (zh) 2011-11-03 2013-07-01 Genentech Inc 烷基化哌□化合物
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US8669251B2 (en) * 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
WO2013157021A1 (fr) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales de ceux-ci
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN104603124B (zh) 2012-08-10 2018-04-17 勃林格殷格翰国际有限公司 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
CN104812746B (zh) * 2012-11-16 2017-03-08 弗·哈夫曼-拉罗切有限公司 布鲁顿氏酪氨酸激酶抑制剂
EP2925323B1 (fr) * 2012-11-30 2017-05-17 F. Hoffmann-La Roche AG Inhibiteur de tyrosine kinase de bruton
EP2964627B1 (fr) * 2013-03-05 2017-03-01 F. Hoffmann-La Roche AG Inhibiteurs de tyrosine kinase de bruton
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
HK1214820A1 (zh) * 2013-07-03 2016-08-05 豪夫迈．罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
WO2015012149A1 (fr) 2013-07-26 2015-01-29 カルナバイオサイエンス株式会社 Nouveau dérivé triazine
EP3048102A1 (fr) * 2013-09-20 2016-07-27 Carna Biosciences Inc. Dérivé de triazine d'un nouveau type
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
EP3042903B1 (fr) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Composés hétéro-bicycliques substitués, compositions et leurs applications médicales
RS58961B1 (sr) 2015-01-22 2019-08-30 Sanofi Aventis Deutschland Proces proizvodnje 2-[4-(ciklopropankarbonil)fenil]-2-metil-propannitrila
EP3365335B1 (fr) 2015-10-23 2024-02-14 Array Biopharma, Inc. Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
EP3876939A4 (fr) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations
WO2020097396A1 (fr) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Dérivés de benzimidazole et dérivés d'aza-benzimidazole en tant qu'inhibiteurs de janus kinase 2 et leurs utilisations
WO2020131627A1 (fr) 2018-12-19 2020-06-25 Array Biopharma Inc. Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
CA3156828A1 (fr) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase tricycliques et leurs utilisations
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (fr) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-hétéroaryloxy benzimidazoles et azabenzimidazoles utilisés en tant qu'inhibiteurs de jak2
WO2023009709A1 (fr) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Pyrazolo pipérazines en tant qu'inhibiteurs de jak2
CA3234638A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CN115073299B (zh) * 2022-06-14 2024-06-25 爱斯特（成都）生物制药股份有限公司 一种制备2-氟-3-三氟甲基苯胺的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683064B2 (en) * 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2420846T3 (es) * 2008-02-05 2013-08-27 F. Hoffmann-La Roche Ag Nuevas piridinonas y piridazinonas
PE20100851A1 (es) 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
US8669251B2 (en) * 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
US9192664B2 (en) * 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis

Also Published As

Publication number Publication date
CN103748088A (zh) 2014-04-23
US20130045965A1 (en) 2013-02-21
PH12014500128A1 (en) 2014-02-24
CO6842020A2 (es) 2014-01-20
WO2013024078A1 (fr) 2013-02-21
HK1197060A1 (en) 2015-01-02
ZA201400739B (en) 2016-01-27
BR112014003582A2 (pt) 2017-03-14
AR087543A1 (es) 2014-04-03
IL230561A0 (en) 2014-03-31
EP2744804B1 (fr) 2017-05-17
EP2744804A1 (fr) 2014-06-25
PE20140865A1 (es) 2014-07-19
AU2012296888A1 (en) 2014-01-23
EA024689B1 (ru) 2016-10-31
US8889682B2 (en) 2014-11-18
JP2014521734A (ja) 2014-08-28
CL2014000350A1 (es) 2014-08-22
EA201490452A1 (ru) 2014-05-30
CR20140027A (es) 2014-03-13
MX349372B (es) 2017-07-26
KR20140052032A (ko) 2014-05-02
MX2014001653A (es) 2014-03-21
TW201311669A (zh) 2013-03-16
JP5823616B2 (ja) 2015-11-25
CA2841801A1 (fr) 2013-02-21
ECSP14013212A (es) 2014-03-31

Similar Documents

Publication Publication Date Title
MA35112B1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA34465B1 (fr) Inhibiteurs de tyrosine kinase de bruton
DE602004013563D1 (de) Rantagonisten
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
MA31763B1 (fr) Inhibiteurs de kinase de type polo
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
FR2938437B1 (fr) Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
MA33768B1 (fr) Triazolopyridines
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
PH12014500128A1 (en) Inhibitors of bruton's tyrosine kinase
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
WO2006031513A3 (fr) Antagonistes des recepteurs cgrp d'aryle-spirolactame